ChemoCentryx Stock Jumps On Amendment In Avacopan Application, New Goal Date Of October 7

Loading...
Loading...
  • Following consultations with the FDA, ChemoCentryx Inc CCXI filed an amendment to its marketing application seeking approval for avacopan to treat Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis addressing concerns raised during the FDA Advisory Committee meeting in May.
  • The FDA has indicated that the filing constitutes a significant amendment to the NDA and will result in the setting of a new PDUFA goal date of October 7. 
  • The application is primarily based on data from the Phase 3 ADVOCATE trial of avacopan.
  • In May, the FDA's Arthritis Advisory Committee voted 9-9 on whether the efficacy data support avacopan approval, 10-8 that the safety profile of avacopan is adequate, and 10-8 that the benefit-risk profile is sufficient.
  • ANCA-associated vasculitis is a systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. 
  • Price Action: CCXI shares are up 8.9% at $14.35 during the premarket session on the last check Tuesday.
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralBriefsVasculitis
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...